| Literature DB >> 28785092 |
Daniel Gallego-Perez1,2,3,4, Durba Pal1,4, Subhadip Ghatak1,4, Veysi Malkoc3,5, Natalia Higuita-Castro1,4, Surya Gnyawali1,4, Lingqian Chang2,3, Wei-Ching Liao3, Junfeng Shi3,6, Mithun Sinha1,4, Kanhaiya Singh1,4, Erin Steen1, Alec Sunyecz1,4,5, Richard Stewart1,4, Jordan Moore1,4, Thomas Ziebro6, Robert G Northcutt6, Michael Homsy5, Paul Bertani7, Wu Lu7, Sashwati Roy1,4, Savita Khanna1,4, Cameron Rink1,4, Vishnu Baba Sundaresan6, Jose J Otero4,8,9, L James Lee3,4,5, Chandan K Sen1,4.
Abstract
Although cellular therapies represent a promising strategy for a number of conditions, current approaches face major translational hurdles, including limited cell sources and the need for cumbersome pre-processing steps (for example, isolation, induced pluripotency). In vivo cell reprogramming has the potential to enable more-effective cell-based therapies by using readily available cell sources (for example, fibroblasts) and circumventing the need for ex vivo pre-processing. Existing reprogramming methodologies, however, are fraught with caveats, including a heavy reliance on viral transfection. Moreover, capsid size constraints and/or the stochastic nature of status quo approaches (viral and non-viral) pose additional limitations, thus highlighting the need for safer and more deterministic in vivo reprogramming methods. Here, we report a novel yet simple-to-implement non-viral approach to topically reprogram tissues through a nanochannelled device validated with well-established and newly developed reprogramming models of induced neurons and endothelium, respectively. We demonstrate the simplicity and utility of this approach by rescuing necrotizing tissues and whole limbs using two murine models of injury-induced ischaemia.Entities:
Mesh:
Year: 2017 PMID: 28785092 PMCID: PMC5814120 DOI: 10.1038/nnano.2017.134
Source DB: PubMed Journal: Nat Nanotechnol ISSN: 1748-3387 Impact factor: 39.213